Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
Jacob Sands, MD
Aaron Lisberg, MD
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
Charles Turck, PharmD, BCPS, BCCCP
Thomas Egenod, MD
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Ben Park, MD, PhD
Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial
Alex Spira, MD, PhD, FACP
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
Tanya Dorff, MD
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
Nicoletta Colombo, MD
Susana Campos, MD, MPH
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
Ritu Salani, MD, MBA
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
Rana McKay, MD
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.